Information Provided By:
Fly News Breaks for November 6, 2019
IMMU
Nov 6, 2019 | 05:07 EDT
Piper Jaffray analyst Joseph Catanzaro raised his price target for Immunomedics to $25 from $20 after hosting meetings with management. The analyst came away "a bit more confident" in a Q2 of 2020 approval for sacituzumab govitecan. Immunomedics emphasized that since the Complete Response Letter it has undertaken a holistic overhaul of manufacturing and that the FDA is in alignment and seemingly eager to get this re-submission filed with no indication that it wants to see confirmatory Ascent data ahead of potential approval, Catanzaro tells investors in a research note. He keeps an Overweight rating on the shares.
News For IMMU From the Last 2 Days
There are no results for your query IMMU